Safety Aspects of Genetically Modified Lactic Acid Bacteria
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Lactic acid bacteria (LAB) have a long history of use in the food industry. Some species are part of the normal human microbiota and have beneficial properties for human health. Their long-standing use and considerable biotechnological potential have led to the development of various systems for their engineering. Together with novel approaches such as CRISPR-Cas, the established systems for engineering now allow significant improvements to LAB strains. Nevertheless, genetically modified LAB (GM-LAB) still encounter disapproval and are under extensive regulatory requirements. This review presents data on the prospects for LAB to obtain ‘generally recognized as safe’ (GRAS) status. Genetic modification of LAB is discussed, together with problems that can arise from their engineering, including their dissemination into the environment and the spread of antibiotic resistance markers. Possible solutions that would allow the use of GM-LAB are described, such as biocontainment, alternative selection markers, and use of homologous DNA. The use of GM-LAB as cell factories in closed systems that prevent their environmental release is the least problematic aspect, and this is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · cited 1×
“Cas9 uses a guide-RNA to form base pairs with the target DNA sequence, which is then followed by cleavage of this DNA and introduction of a site-specific double-strand break [44].”
BackgroundRepurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 1×
“CRISPR interference is achieved by specific single-guide-RNA-guided binding of nuclease-inactivated Cas9 to target genes and promoters that leads to obstruction of RNA polymerase [49].”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 1×
“Another improvement to the field is base editing, where a fusion protein that contains a catalytically impaired Cas9 variant coupled to cytidine deaminase allows C to T (or G to A) substitutions [10,55,56].”
BackgroundLinares, D. M., Gómez, C., Renes, E., Fresno, J. M., Tornadijo, M. E., Ross, R. P., & Stanton, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00846 · Cited by 335
Brodmann, T., Endo, A., Gueimonde, M., Vinderola, G., Kneifel, W., de Vos, W. M., Salminen, S., & Gómez-Gallego, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01725 · Cited by 191 · cited 1×
“Whereas GRAS status applies to the regulatory framework in the USA, in Europe, the EFSA uses the Qualified Presumption of Safety (QPS) procedure to evaluate products with microorganisms and to assess the risks associated with human, animal, and environmental use [6].”
MethodLadero, V., Ramos, A., Wiersma, A., Goffin, P., Schanck, A., Kleerebezem, M., Hugenholtz, J., Smid, E. J., & Hols, P. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.02304-06 · Cited by 127
Antibiotic-free selection in biotherapeutics: Now and forever
Mignon, C., Sodoyer, R., & Werle, B. (2015) · Pathogens · doi:10.3390/pathogens4020157 · Cited by 87 · cited 1×
“According to their mechanisms of action, these systems can be based on auxotrophic, nonantibiotic dominant and complementary markers, post-segregational killing, RNA interference, or de-repression of an essential gene or minicircle [88].”
Background
Cited by
Marco, M. L., Sanders, M. E., Gänzle, M., Arrieta, M. C., Cotter, P. D., De Vuyst, L., Hill, C., Holzapfel, W., Lebeer, S., Merenstein, D., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00390-5 · Cited by 937
Engineered living biomaterials
Rodrigo-Navarro, A., Sankaran, S., Dalby, M. J., del Campo, A., & Salmeron-Sanchez, M. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00350-8 · Cited by 494
Engineering living therapeutics with synthetic biology
Cubillos-Ruiz, A., Guo, T., Sokolovska, A., Miller, P. F., Collins, J. J., Lu, T. K., & Lora, J. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00285-3 · Cited by 356
Castro-López, C., García, H. S., Guadalupe Martínez-Ávila, G. C., González-Córdova, A. F., Vallejo-Cordoba, B., & Hernández-Mendoza, A. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.12.017 · Cited by 72
Zafar, H., Ain, N. U., Alshammari, A., Alghamdi, S., Raja, H., Ali, A., Siddique, A., Tahir, S. D., Akbar, S., Arif, M., et al. (2022) · Nutrients · doi:10.3390/nu14081654 · Cited by 41
Metadata
- Authors
- Plavec, T. V., & Berlec, A.
- Venue
- Microorganisms
- Publisher
- MDPI AG
- Published
- 2020-02-21
- Volume
- 8
- Issue
- 2
- Pages
- 297
- ISSN
- 2076-2607 (ISSN-L)
- OpenAlex
- W3008061051
- Cited by
- 156
- References
- 7
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety Aspects of Genetically Modified Lactic Acid Bacteria. https://app.cochat.ai/papers/10.3390/microorganisms8020297
- The paper
- Plavec, T. V., & Berlec, A. (2020). Safety Aspects of Genetically Modified Lactic Acid Bacteria. Microorganisms. https://doi.org/10.3390/microorganisms8020297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.